Cargando…
Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
PURPOSE: Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Se...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988792/ https://www.ncbi.nlm.nih.gov/pubmed/36811765 http://dx.doi.org/10.1007/s11060-023-04256-z |
_version_ | 1784901642173284352 |
---|---|
author | Pei, Jian Li, Pei Gao, Yun H. Tian, Bao G. Wang, Da Y. Zheng, Yu Liu, Li Y. Zhang, Zhi Y. Huang, Si S. Wen, Min Xu, Xiang Xia, Lei |
author_facet | Pei, Jian Li, Pei Gao, Yun H. Tian, Bao G. Wang, Da Y. Zheng, Yu Liu, Li Y. Zhang, Zhi Y. Huang, Si S. Wen, Min Xu, Xiang Xia, Lei |
author_sort | Pei, Jian |
collection | PubMed |
description | PURPOSE: Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. METHODS: We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. RESULTS: A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (p = 0.0132) than the brain-invasive group, which showed moderate intensity. CONCLUSION: This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04256-z. |
format | Online Article Text |
id | pubmed-9988792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-99887922023-03-08 Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) Pei, Jian Li, Pei Gao, Yun H. Tian, Bao G. Wang, Da Y. Zheng, Yu Liu, Li Y. Zhang, Zhi Y. Huang, Si S. Wen, Min Xu, Xiang Xia, Lei J Neurooncol Research PURPOSE: Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. METHODS: We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. RESULTS: A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (p = 0.0132) than the brain-invasive group, which showed moderate intensity. CONCLUSION: This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04256-z. Springer US 2023-02-22 2023 /pmc/articles/PMC9988792/ /pubmed/36811765 http://dx.doi.org/10.1007/s11060-023-04256-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Pei, Jian Li, Pei Gao, Yun H. Tian, Bao G. Wang, Da Y. Zheng, Yu Liu, Li Y. Zhang, Zhi Y. Huang, Si S. Wen, Min Xu, Xiang Xia, Lei Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) |
title | Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) |
title_full | Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) |
title_fullStr | Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) |
title_full_unstemmed | Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) |
title_short | Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) |
title_sort | type iv collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (lc-ms/ms) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988792/ https://www.ncbi.nlm.nih.gov/pubmed/36811765 http://dx.doi.org/10.1007/s11060-023-04256-z |
work_keys_str_mv | AT peijian typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT lipei typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT gaoyunh typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT tianbaog typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT wangday typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT zhengyu typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT liuliy typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT zhangzhiy typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT huangsis typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT wenmin typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT xuxiang typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms AT xialei typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms |